Quintiles has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas around the globe.
Quintiles is expected to assume the operational responsibilities for the majority of AstraZeneca’s clinical pharmacology delivery. AstraZeneca and Quintiles will work together, focusing their efforts on leveraging leading-edge science and establishing operational efficiency and consistency to support AstraZeneca’s goal to shorten delivery timelines and bring innovative medicines more quickly to patients.
Ron Wooten, executive vice president of corporate development at Quintiles, said: “We are delighted to be AstraZeneca’s dedicated clinical pharmacology alliance strategic partner. Our experience in managing such partnerships will be key as we work together on this important project.”
Anders Ekblom, executive vice president for global drug development at AstraZeneca, said: “This model gives us access to the right scientific and medical expertise plus the quality, flexibility and capacity we need to work efficiently and cost-effectively to deliver these studies. Finding more efficient ways to do our work, whilst maintaining the highest quality, is one of AstraZeneca’s key priorities.”